This company has been acquired
NVCN Stock Overview
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Neovasc Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$40.15 |
| 52 Week High | CA$41.20 |
| 52 Week Low | CA$6.00 |
| Beta | 1.98 |
| 1 Month Change | 0.35% |
| 3 Month Change | 39.90% |
| 1 Year Change | 224.44% |
| 3 Year Change | -56.12% |
| 5 Year Change | -97.32% |
| Change since IPO | -99.98% |
Recent News & Updates
Shareholder Returns
| NVCN | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 0.6% | 6.5% | 2.5% |
| 1Y | 224.4% | -15.6% | 10.3% |
Return vs Industry: NVCN exceeded the Canadian Medical Equipment industry which returned -20.8% over the past year.
Return vs Market: NVCN exceeded the Canadian Market which returned -8.9% over the past year.
Price Volatility
| NVCN volatility | |
|---|---|
| NVCN Average Weekly Movement | 10.5% |
| Medical Equipment Industry Average Movement | 10.4% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in CA Market | 18.0% |
| 10% least volatile stocks in CA Market | 4.1% |
Stable Share Price: NVCN's share price has been volatile over the past 3 months.
Volatility Over Time: NVCN's weekly volatility (10%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 60 | Fred Colen | neovasc.com |
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008.
Neovasc Inc. Fundamentals Summary
| NVCN fundamental statistics | |
|---|---|
| Market cap | CA$110.78m |
| Earnings (TTM) | -CA$55.39m |
| Revenue (TTM) | CA$5.11m |
21.7x
P/S Ratio-2.0x
P/E RatioIs NVCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCN income statement (TTM) | |
|---|---|
| Revenue | US$3.81m |
| Cost of Revenue | US$5.07m |
| Gross Profit | -US$1.27m |
| Other Expenses | US$39.93m |
| Earnings | -US$41.20m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.93 |
| Gross Margin | -33.37% |
| Net Profit Margin | -1,082.90% |
| Debt/Equity Ratio | 79.8% |
How did NVCN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/13 20:24 |
| End of Day Share Price | 2023/04/10 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neovasc Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Jason Mills | Canaccord Genuity |
| John Gillings | Citizens JMP Securities, LLC |